Filing identity and reporting period
Important discrepancy: The request identifies Adicet Bio, Inc., but the supplied filing is resTORbio, Inc.’s Form 10-K, filed March 18, 2019. It covers the fiscal year ended December 31, 2018, with fourth-quarter data; it is not an Adicet Bio filing.
resTORbio was a clinical-stage biopharmaceutical company developing RTB101, an oral TORC1 inhibitor, primarily for reducing respiratory tract infections in older adults. It had no approved products and had generated no product revenue.
Financial results and position
| Metric | FY 2018 | FY 2017 |
|---|---|---|
| Revenue | $0 | $0 |
| Research and development expense | $31.1 million | $16.8 million |
| General and administrative expense | $8.6 million | $2.0 million |
| Total operating expenses / operating loss | $39.7 million | $18.9 million |
| Net loss | $37.6 million | $33.8 million |
| Net loss per share, basic and diluted | $1.42 | $8.42 |
| Operating cash flow | $(35.5) million | $(11.0) million |
For Q4 2018, operating expenses were $6.36 million and net loss was $5.76 million, versus $7.52 million and $23.05 million, respectively, in Q4 2017. The unusually large Q4 2017 loss included a $14.9 million noncash expense from revaluing preferred-stock tranche rights. Profit margins are not meaningful given the absence of revenue and continuing losses.
At December 31, 2018, cash and cash equivalents were $7.0 million and marketable securities were $101.0 million, totaling $108.0 million; total current liabilities were $5.7 million and total stockholders’ equity was $104.2 million. The filing reports no credit facility or committed capital source and no material debt. Management estimated available funds would support operations into at least Q2 2020, subject to assumptions and execution.
Material changes versus prior period
- R&D expense rose $14.2 million year over year, principally reflecting clinical-trial activity, including the Phase 2b trial, and related development costs. G&A rose $6.6 million, including increased personnel and public-company costs.
- Net loss increased $3.8 million, despite the absence in 2018 of the prior-year $14.9 million tranche-rights revaluation expense; 2018 included $2.1 million of other income, primarily interest.
- Cash used in operations increased from $11.0 million to $35.5 million. Investing cash outflow mainly reflected purchases of marketable securities, not operating investment; the 2018 IPO provided about $89.4 million net proceeds.
Outlook, commentary and risks
- Phase 2b results: RTB101 10 mg once daily reduced the percentage of high-risk elderly subjects with one or more laboratory-confirmed RTIs by 30.6% versus placebo (p=0.025). The twice-daily dose and RTB101 plus everolimus did not meet the primary endpoint. The company reported no observed benefit in current smokers or COPD patients.
- Management planned two placebo-controlled Phase 3 trials in 2019, enrolling people 65 and older while excluding current smokers and COPD patients. Topline results were expected in 2020. These are forward-looking plans, not reported outcomes.
- Key risks include Phase 3 failure or delay, uncertain safety and regulatory approval, seasonal trial enrollment, reliance on third-party manufacturers and CROs, limited commercial infrastructure, and the need for additional financing. The company estimated its existing funds would not cover all planned development.
- The Novartis license carries potential clinical and regulatory milestones, up to $125 million in commercial milestones, and tiered royalties. No remaining milestones or royalties had been reached or were considered probable at year-end.
- Management reported disclosure controls and internal control over financial reporting effective as of year-end. The independent auditor issued an unqualified opinion on the consolidated financial statements but did not audit internal control effectiveness.
Important facts for investors to verify
- Confirm the issuer: this supplied filing is for resTORbio, not Adicet Bio.
- Review subsequent filings for whether the planned Phase 3 trials began, enrolled, and met their endpoints, and for any changes to the stated cash runway.
- Assess financing needs, dilution and use of the $50 million at-the-market offering authorization disclosed after year-end.
- Verify the clinical evidence, including trial populations and exclusions, endpoint definitions, statistical analyses, and whether findings replicated in pivotal trials.
- Review Novartis license obligations, manufacturing arrangements, and any later changes in pipeline or corporate status.